Health
Trump’s Tariff Threat Spotlights Drugmakers’ US Factory Progress
The new duties could hit about $220 billion of US pharmaceutical imports.
Photographer: Eric Thayer/BloombergPresident Donald Trump’s plan to impose a 100% tariff on branded and patented drugs could sharply raise costs for pharmaceutical companies without US manufacturing capacity, raising pressure on firms that have yet to break ground.
The move threatens to double the cost of global pharma’s blockbuster treatments ranging from cancer immunotherapies to weight-loss shots if construction doesn’t begin by the Oct. 1 deadline. Companies including Novartis AG and Sanofi SA have announced large US investments, though it isn’t clear from public disclosures how far those projects have progressed.